Forte Biosciences Inc. (FBRX)
NASDAQ: FBRX
· Real-Time Price · USD
10.96
-0.11 (-0.99%)
At close: Sep 04, 2025, 3:59 PM
10.96
0.00%
After-hours: Sep 04, 2025, 04:10 PM EDT
-0.99% (1D)
| Bid | 10.5 |
| Market Cap | 136.26M |
| Revenue (ttm) | 38K |
| Net Income (ttm) | -42.45M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -2.98 |
| Forward PE | -3.32 |
| Analyst | Buy |
| Ask | 11.65 |
| Volume | 27,530 |
| Avg. Volume (20D) | 99,445 |
| Open | 11.21 |
| Previous Close | 11.07 |
| Day's Range | 10.65 - 11.28 |
| 52-Week Range | 4.11 - 28.68 |
| Beta | 2.91 |
About FBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+2.94%
Forte Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
2 months ago
-25.26%
Forte Biosciences shares are trading lower after the company announced the pricing of a $75 million public offering.
2 months ago · businesswire.com
Forte Biosciences Announces Pricing of $75 Million Public OfferingDALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ...
2 months ago · businesswire.com
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B StudyDALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...